HomeComparePROCW vs ORCC

PROCW vs ORCC: Dividend Comparison 2026

PROCW yields 10309.28% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROCW wins by $74444449017686400.00M in total portfolio value
10 years
PROCW
PROCW
● Live price
10309.28%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$74444449017686400.00M
Annual income
$73,050,544,679,942,830,000,000.00
Full PROCW calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — PROCW vs ORCC

📍 PROCW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROCWORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROCW + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROCW pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROCW
Annual income on $10K today (after 15% tax)
$876,288.66/yr
After 10yr DRIP, annual income (after tax)
$62,092,962,977,951,410,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, PROCW beats the other by $62,092,962,977,951,410,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROCW + ORCC for your $10,000?

PROCW: 50%ORCC: 50%
100% ORCC50/50100% PROCW
Portfolio after 10yr
$37222224508843200.00M
Annual income
$36,525,272,339,971,417,000,000.00/yr
Blended yield
98.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

PROCW
No analyst data
Altman Z
0.9
Piotroski
6/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROCW buys
0
ORCC buys
0
No recent congressional trades found for PROCW or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROCWORCC
Forward yield10309.28%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$74444449017686400.00M$21.4K
Annual income after 10y$73,050,544,679,942,830,000,000.00$1.04
Total dividends collected$74351742623648800.00M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: PROCW vs ORCC ($10,000, DRIP)

YearPROCW PortfolioPROCW Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$1,041,628$1,030,927.84$11,190$489.61+$1.03MPROCW
2$101,473,713$100,359,170.93$12,229$256.01+$101.46MPROCW
3$9,245,800,644$9,137,223,771.45$13,216$130.74+$9245.79MPROCW
4$787,968,000,080$778,074,993,390.97$14,207$66.02+$787967.99MPROCW
5$62,816,013,853,671$61,972,888,093,585.02$15,234$33.17+$62816013.84MPROCW
6$4,684,424,446,980,322$4,617,211,312,156,894.00$16,317$16.62+$4684424446.96MPROCW
7$326,809,221,096,547,600$321,796,886,938,278,660.00$17,468$8.32+$326809221096.53MPROCW
8$21,331,166,081,354,670,000$20,981,480,214,781,362,000.00$18,695$4.16+$21331166081354.65MPROCW
9$1,302,714,334,339,765,600,000$1,279,889,986,632,716,000,000.00$20,006$2.08+$1302714334339765.75MPROCW
10$74,444,449,017,686,390,000,000$73,050,544,679,942,830,000,000.00$21,407$1.04+$74444449017686400.00MPROCW

PROCW vs ORCC: Complete Analysis 2026

PROCWStock

Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately ten therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg City, Luxembourg.

Full PROCW Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this PROCW vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROCW vs SCHDPROCW vs JEPIPROCW vs OPROCW vs KOPROCW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.